C&EN White Paper
Concept to Commercialization: The Role of CDMOs in Driving Pharma Innovation Through Phase-Appropriate Technology Transfers
Brought to you by Veranova

Contract Development & Manufacturing Organizations (CDMOs) are crucial in driving innovation within the pharma industry. Companies are increasingly leveraging the expertise of CDMOs through technology transfers to foster innovation and accelerate the growth of new drugs.

Technology transfer is essential at various stages of drug development, from preclinical phases to commercialization. This white paper highlights the significance of CDMOs in advancing pharmaceutical development and discusses the benefits of collaboration for efficient, cost-effective and high-quality drug development processes.

Key Objectives:
  • What is a ‘technology transfer’ between originator and CDMO
  • The technology transfer cycle from preclinical to commercial stage
  • How to initiate the technology transfer process
  • How a CDMO can ensure continuous improvement in their technology transfer
  • Factors affecting a successful technology transfer

Brought to you by:
This content was created by Veranova, without editorial input from the C&EN Media Group. For more information on C&EN's custom products, visit our C&EN Media Kit.
Please complete the form to download the white paper.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

Copyright © 2023 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy